Xeris Biopharma Holdings, Inc. provided revenue guidance for the full year 2024. For the year, the company expects tightening 2024 total revenue guidance to $175 million to $200 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | -1.04% | -4.50% | -18.72% |
May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.72% | 286M | |
+37.94% | 727B | |
-7.89% | 354B | |
+15.48% | 328B | |
-0.39% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.11% | 164B | |
-1.82% | 164B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024